Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

June 30, 2010

Study Completion Date

August 31, 2010

Conditions
Mesothelioma
Interventions
DRUG

bevacizumab

15 mg/kg IV every 3 weeks

DRUG

cisplatin

75 mg/m2 IV every 3 weeks

DRUG

pemetrexed

500 mg/m2 every 3 weeks

Trial Locations (1)

75390-8852

University of Texas Southwestern Medical Center, Dallas

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

University of Chicago

OTHER

collaborator

Columbia University

OTHER

collaborator

Duke University

OTHER

lead

University of Texas Southwestern Medical Center

OTHER